Adaptive Biotechnologies Corporation Common Stock
Here’s whether Adaptive Biotechnologies Corporation Common Stock (ADPT) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+9.77% over 10 days); RSI 54 — healthy momentum range; strong 1-year return of +108.9%; 3-month momentum positive (+57.5%). Concerns: declining volume on rally — weak conviction (0.74x 30d avg). Currently 3.8% off its 52-week high. Score: +6/7.
ADPT is in a confirmed uptrend, trading above both its 50-day ($18.22) and 200-day ($16.39) moving averages. An RSI of 53.8 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +108.9% compares to +20.4% for SPY (beat the market by 88.5%).